公开(公告)号：US09982046B2

公开(公告)日：2018-05-29

申请号：US15346026

申请日：2016-11-08

Applicant: NOVARTIS AG

Inventor： Kurt Alex Heldwein ,  Igor Splawski ,  Jennifer Brogdon ,  Joshua Goldstein ,  William Dole ,  John Trauger ,  Chonghui Zhang

IPC: A61P9/08 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61K39/395 ,  C07K16/28 ,  A61K9/00 ,  A61K45/06 ,  C07K14/47 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K9/0019 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61P9/04 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  C07K14/4726 ,  C07K16/2851 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US09988455B2

公开(公告)日：2018-06-05

申请号：US15390067

申请日：2016-12-23

Applicant: NOVARTIS AG

Inventor： Kurt Alex Heldwein ,  Jennifer Brogdon ,  William Dole ,  John Trauger ,  Yuting Tang ,  Julia Neugebauer ,  Annika Schmid

IPC: A61P9/08 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61K39/395 ,  C07K16/28 ,  C07K14/47

CPC classification number: C07K16/2851 ,  A61K39/3955 ,  A61K2039/505 ,  A61P9/04 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  C07K14/33 ,  C07K14/4726 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.